Regeneron Pharmaceuticals, Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 16.07B | 12.17B | 13.12B | 14.20B | 14.34B | 1.0% | |
| Cost of Revenue | (2.72B) | (1.71B) | (2.24B) | (1.97B) | (2.10B) | 6.6% | |
Gross Profit | 13.35B | 10.47B | 10.87B | 12.23B | 12.24B | 0.1% | |
| Operating Expenses | |||||||
| Research & Development | (2.62B) | (3.06B) | (3.99B) | (5.23B) | (5.85B) | 11.8% | |
| Selling, General & Administrative | (1.82B) | (2.12B) | (2.54B) | (2.95B) | (2.70B) | -8.6% | |
| Depreciation & Amortization | (286.20M) | (341.40M) | (421.00M) | (482.90M) | (543.70M) | 12.6% | |
Operating Income (EBIT) | 8.95B | 5.39B | 4.35B | 3.99B | 3.58B | -10.3% | |
| Non-Operating Items | |||||||
| Interest Income | — | 160.10M | 495.90M | 711.40M | 716.80M | 0.8% | |
| Interest Expense | (57.30M) | (59.40M) | (73.00M) | (55.20M) | (43.80M) | -20.7% | |
| Other Income/Expenses (Net) | 379.00M | -526.80M | -149.30M | 789.20M | 1.65B | 109.4% | |
Income Before Tax | 9.33B | 4.86B | 4.20B | 4.78B | 5.23B | 9.4% | |
| Income Tax Expense | (1.25B) | (520.40M) | (245.70M) | (367.30M) | (725.80M) | 97.6% | |
Net Income | 8.08B | 4.34B | 3.95B | 4.41B | 4.50B | 2.1% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $76 | $41 | $37 | $41 | $43 | 5.3% | |
| Weighted Avg Shares Outstanding | 105.70M | 107.10M | 106.70M | 107.90M | 104.60M | -3.1% | |
| Weighted Avg Shares Outstanding (Diluted) | 112.20M | 113.50M | 113.70M | 115.10M | 108.60M | -5.6% | |
EBITDA | 9.67B | 5.26B | 4.69B | 5.32B | 5.82B | 9.4% |
Explore REGN
REGN in the Healthcare
Large Cap